Moderna (MRNA.US) stock erased all of the pre-market gains and is trading nearly 1.5% lower despite Jefferies upgrading its stance on the drug maker to ‘buy’ from ‘hold’, highlighting the company's opportunities in the field of cancer therapy.
The analysts also lifted the price target to $275 per share from $170, which indicates approximately 44.0 % upside potential from current price levels. “The Covid story is mostly understood and behind us and no longer the thesis on the stock,” wrote analyst Michael Yee.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app“We see stock rebounding back up in 2023, a return of pipeline opportunities and a "story stock" as generalist and HC interest revisits the stock,” the analysts added in an upgrade note.
Yee also believes that the drug maker's experimental respiratory syncytial virus vaccine results could positively affect its share price.
Moderna (MRNA.US) stock price is down almost 24% year-to-date and has been moving sideways since March 2022. Recently price pulled back sharply, as buyers did not manage to keep the price above local resistance at $203.50, which coincides with 23.6% Fibonacci retracement of the last downward correction. If current sentiment prevails another downward impulse towards major support at $152.40 may be launched. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
